Top Page
China Medical System Holdings
(OTC:0867)
China Medical System Holdings (0867) vs. S&P 500 (SPY)
China Medical System Holdings Business Overview & Revenue Model
China Medical System Holdings Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 7.01B | 8.01B | 9.15B | 8.34B | 6.95B | 6.07B | Gross Profit |
| 5.17B | 6.11B | 7.04B | 6.25B | 5.13B | 4.55B | EBIT |
| 1.67B | 2.71B | 4.02B | 3.87B | 3.28B | 2.64B | EBITDA |
| 1.89B | 2.92B | 3.85B | 3.70B | 3.05B | 2.75B | Net Income Common Stockholders |
| 1.39B | 2.40B | 3.26B | 3.02B | 2.53B | 1.96B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 918.98M | 6.14B | 5.87B | 4.36B | 2.67B | 1.37B | Total Assets |
| 1.48B | 17.73B | 17.75B | 15.81B | 12.70B | 11.17B | Total Debt |
| 28.26M | 1.30B | 1.81B | 1.71B | 600.16M | 713.79M | Net Debt |
| -890.47M | -3.01B | -2.56B | -1.67B | -2.07B | -651.22M | Total Liabilities |
| 154.00M | 2.17B | 3.02B | 2.96B | 1.60B | 1.65B | Stockholders Equity |
| 1.33B | 15.52B | 14.59B | 12.75B | 11.03B | 9.47B |
| Cash Flow | Free Cash Flow | ||||
| 1.86B | 2.18B | 3.03B | 2.31B | 2.35B | 2.21B | Operating Cash Flow |
| 1.88B | 2.50B | 3.55B | 2.49B | 2.69B | 2.56B | Investing Cash Flow |
| -839.91M | -442.28M | -1.18B | -1.52B | -353.82M | -309.39M | Financing Cash Flow |
| -1.55B | -2.13B | -1.40B | -258.39M | -1.03B | -1.70B |
China Medical System Holdings Technical Analysis
China Medical System Holdings Peers Comparison
China Medical System Holdings Corporate Events
China Medical System Holdings Limited announced the successful passage of all proposed resolutions at its Annual General Meeting held on April 24, 2025. The resolutions, which included the adoption of financial statements, approval of a final dividend, and re-election of directors, were passed with overwhelming support, indicating strong shareholder confidence in the company’s strategic direction.
China Medical System Holdings has announced its proposal to spin off its subsidiary, Dermavon Holdings Limited, and list it separately on the Main Board of the Stock Exchange of Hong Kong. This move is expected to provide Dermavon with a new financing platform, improve its corporate image, and enhance its business profile, allowing it to independently raise funds and focus on its core business. The spin-off aims to incentivize employees, improve transparency, and potentially offer higher returns to shareholders.
China Medical System Holdings Limited has announced proposed amendments to its memorandum and articles of association, which include provisions for electronic proxy submissions, electronic voting, and the removal of manual signature requirements for transfer instruments. These changes aim to modernize the company’s operations and improve efficiency, subject to shareholder approval at the upcoming Annual General Meeting.
China Medical System Holdings Limited has announced its upcoming Annual General Meeting (AGM) scheduled for April 24, 2025, in Hong Kong. Key agenda items include the adoption of the 2024 financial statements, approval of a final dividend, re-election of directors, and re-appointment of auditors. The company also seeks shareholder approval to authorize the board to issue new shares, which could impact its capital structure and market positioning.
China Medical System Holdings Limited announced a final cash dividend of RMB 0.1174 per share for the financial year ending December 31, 2024. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.0841, with a payment date set for May 9, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may influence investor sentiment positively.
China Medical System Holdings Limited announced its annual results for the year ending December 31, 2024, reporting a decline in turnover and profit due to the impact of the National Volume-Based Procurement (VBP) policy. Despite these challenges, the company made significant strides in its R&D efforts, with several innovative drugs approved for marketing and others submitted for approval. The company’s focus on exclusive and innovative products resulted in a 4.1% increase in revenue from non-VBP products, accounting for over half of the total revenue. This strategic emphasis on innovation aims to strengthen the company’s market position and drive future growth.
China Medical System Holdings Limited announced that its self-developed innovative drug, CMS-D003, has received approval from China’s National Medical Products Administration to conduct clinical trials. This approval marks a significant step in evaluating CMS-D003’s safety and efficacy for treating symptomatic obstructive hypertrophic cardiomyopathy, potentially enhancing the company’s market position and offering improved treatment options for patients.
China Medical System Holdings Limited has announced a board meeting scheduled for March 17, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the payment of a final dividend, which could have implications for shareholders and the company’s financial strategy.